Novo Nordisk A/S
NONOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,755,596,147 | $3,110,419,808 | $2,147,851,542 | $1,667,095,855 |
| - Cash | $15,655,000 | $14,392,000 | $12,653,000 | $10,720,000 |
| + Debt | $102,787,000 | $27,006,000 | $25,784,000 | $26,645,000 |
| Enterprise Value | $2,842,728,147 | $3,123,033,808 | $2,160,982,542 | $1,683,020,855 |
| Revenue | $290,403,000 | $232,261,000 | $176,954,000 | $140,800,000 |
| % Growth | 25% | 31.3% | 25.7% | – |
| Gross Profit | $245,881,000 | $196,496,000 | $148,506,000 | $117,142,000 |
| % Margin | 84.7% | 84.6% | 83.9% | 83.2% |
| EBITDA | $137,376,000 | $111,041,000 | $76,802,000 | $64,826,000 |
| % Margin | 47.3% | 47.8% | 43.4% | 46% |
| Net Income | $100,988,000 | $83,683,000 | $55,525,000 | $47,757,000 |
| % Margin | 34.8% | 36% | 31.4% | 33.9% |
| EPS Diluted | 22.64 | 9.31 | 12.22 | 10.37 |
| % Growth | 143.2% | -23.8% | 17.8% | – |
| Operating Cash Flow | $120,968,000 | $108,908,000 | $78,887,000 | $55,000,000 |
| Capital Expenditures | -$51,309,000 | -$38,896,000 | -$14,753,000 | -$7,385,000 |
| Free Cash Flow | $69,659,000 | $70,012,000 | $64,134,000 | $47,615,000 |